The Effects of Probiotic Supplementation on Opioid-Related Disorder in Patients under Methadone Maintenance Treatment Programs.

Hamed Mirzaei, Ahmad Reza Saghazade, Samira Abbaszadeh-Mashkani, Amir Ghaderi, Nader Molavi, Morad Rasouli-Azad, Amir Hassan Matini, Hamid Reza Banafshe, Marjan Valiollahzadeh, Majid Hassanzadeh, Peyman Mamsharifi

Journal: International journal of clinical practice 2022;2022():1206914

PMID: 35685534

Free Full Text on PubMed Central View on PubMed

Abstract

INTRODUCTION

Patients under methadone maintenance treatment programs (MMTPs) are susceptible to numerous complications (e.g., mental and metabolic disorders). This study evaluated the effects of probiotics on clinical symptoms, biomarkers of oxidative stress, inflammation, insulin resistance, and serum lipid content in patients receiving MMTPs.

MATERIALS AND METHODS

A randomized, double-blind, placebo-controlled trial was conducted among 70 patients receiving MMTPs to receive either 1.8 × 10 CFU/day probiotics ( = 35) or placebo ( = 35) for 12 weeks. Clinical symptoms and metabolic profiles were measured before and after the intervention in patients receiving MMTPs.

RESULTS

Compared with the placebo group, probiotic supplementation resulted in a significant improvement in the severity of depression ( < 0.05). In addition, probiotic administration significantly decreased fasting plasma glucose (FPG), total cholesterol, and low-density lipoprotein cholesterol (LDL cholesterol) ( < 0.05). Furthermore, probiotics resulted in a significant reduction in high-sensitivity C-reactive protein (hs-CRP) and a significant elevation in total antioxidant capacity (TAC) and total glutathione (GSH) levels ( < 0.05).

CONCLUSION

Treatment with probiotics for 12 weeks to patients receiving MMTPs had beneficial effects on symptoms of depression, as well as several metabolic profiles. Clinical Trial Registration: this study was registered in the Iranian website (https://www.irct.ir) for clinical trials registration (https://fa.irct.ir/trial/46363/IRCT20170420033551N9). The registration date is March 22, 2020.

Address: Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran.; International Center for Comparative Criminology, University of Montreal, Montreal, Canada.; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.; Department of Clinical Pathology, Kashan University of Medical Sciences, Kashan, Iran.; Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.; Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.; Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Trauma Nursing Research Center, Faculty of Nursing and Midwifery, Kashan University of Medical Sciences, Kashan, Iran.; Department of Psychology, Allameh Tabataba'i University, Tehran, Iran.; Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran.

DOI: 10.1155/2022/1206914